66 results about "CYP3A4" patented technology

The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 2 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 2-42 days.

The invention provides a specific probe substrate for a cytochrome P450 3A4 enzyme and an application of the substrate in CYP3A4 enzyme activity measurement. The specific operation flow of the enzyme activity measurement comprises the following steps: carrying out the CYP catalytic reaction of the specific substrate by virtue of a CYP in-vitro incubation system by selecting any monomer in toad steroid series of compounds as a high-specificity probe substrate; and measuring the activity of the CYP3A4 enzyme in each biological sample and each cell by quantitatively detecting a product generated quantity or a substrate eliminated quantity in a unit time. The specific probe substrate provided by the invention can be used for quantitative evaluation of CYP3A4 enzyme activity in biological samples belonging to different species and deriving from different individual sources, and quantitative measurement of CYP3A4 enzyme activity in animal tissue cell culture fluids and cell products deriving from different sources.

Derivatives of dillapiol, sesamol and related monolignans having the following general formula:

These compounds have synergistic properties, inhibit cytochrome P450 enzymes such as human CYP3A4, and can be used as pesticide synergists or pharmaco-enhancers. Accordingly, methods for increasing the efficacy and/or bioavailability of a pharmaceutically active agent and for increasing the potency of a pesticide are described, as are synergistic pesticidal and pharmaceutical compositions.

The invention provides a lentiviral expression vector for specifically promoting high expression of CYP3A4 (cytochrome P450 3A4) gene in hepatocytes. The lentiviral expression vector for specifically promoting high expression of CYP3A4 (cytochrome P450 3A4) gene in hepatocytes comprises fundamental sequences, resistance gene sequences, multiple-cloning-site sequences, promoter subsequences, and CYP3A4 gene cDNA (complementary DNA) sequences in a pLVX-AcGFP-C1 expression vector. Multiple cloning sites include an XhoI restriction enzyme cutting site and an XmaI restriction enzyme cutting site. The CYP3A4 gene cDNA sequences include XhoI restriction enzyme cutting sites, CYP3A4 gene coded sequences and XmaI restriction enzyme cutting sites. The CYP3A4 gene cDNA sequences are forwardly inserted into the multiple-cloning-site sequences. The lentiviral expression vector is capable of expressing the CYP3A4 gene specifically, continuously, efficiently and stably with high transfection efficiency and low consumption, and can be used as a powerful tool applied to pharmaceutical research and development related to CYP3A4.

The present invention provides a desired rat or a rat cell which contains a predefined, specific and desired alteration rendering the rat or rat cell predisposed to alterations in drug and chemical metabolism by modification of its structure or mechanism. Specifically, the invention pertains to a genetically altered rat, or a rat cell in culture, that is defective in at least one of two alleles of a drug metabolism gene such as the Cyp7b1 gene, the Cyp3a4 gene, etc. In another embodiment, the rat cell is a somatic cell. The inactivation of at least one drug metabolism allele results in an animal with a higher susceptibility to altered drug and chemical metabolism. In one embodiment, the genetically altered animal is a rat of this type and is able to serve as a useful model for altered drug and chemical metabolism or toxicology and as a test animal for autoimmune and other studies. The invention additionally pertains to the use of such rats or rat cells, and their progeny in research and medicine. In one embodiment, the invention provides a genetically modified or chimeric rat cell whose genome comprises two chromosomal alleles of a drug metabolism gene wherein at least one of the two alleles contains a mutation, or the progeny of the cell.

The invention relates to a method for detecting in-vivo CYP1A2 and CYP3A4 enzyme activity in earthworm through high-performance liquid chromatography-tandem mass spectrometry, and belongs to the technical field of the enzyme activity detection. The method comprises the following steps: (1) preparing earthworm microsome protein suspension; (2) adding the earthworm microsome protein suspension prepared in the step (1) in an incubation system containing two specific probe primers, warming to start enzymatic reaction, after the enzymatic reaction is terminated, detecting two specific metabolites produced after the enzymatic reaction is terminated by utilizing high-performance liquid chromatography-tandem mass spectrometry, and respectively computing CYP1A2 and CYP3A4 enzyme activity. The detection method disclosed by the invention is high in accuracy and precision and sensitivity, strong in stability, capable of measuring multiple CYP subenzyme activities in the earthworm body, thereby providing a detection method for exploring response mode on the soil pollutant by different CYP subenzyme of the earthworm.

The invention relates to a kit and a method for detecting the polymorphism of a CYP3A4 gene and belongs to the technical field of gene sequencing. The kit comprises primers for detection, wherein the primers for the detection comprise at least one pair in long-fragment amplification specific forward and reverse primers for a first exon to a third exon of the CYP3A4 gene, long-fragment amplification specific forward and reverse primers for a fourth exon to a seventh exon of the CYP3A4 gene, long-fragment amplification specific forward and reverse primers for an eighth exon to an eleventh exon of the CYP3A4 gene and long-fragment amplification specific forward and reverse primers for a twelfth exon and a thirteenth exon of the CYP3A4 gene and at least one pair in forward and reverse sequencing primers for each exon of the CYP3A4 gene corresponding to long-fragment deoxyribose nucleic acid (DNA) of the first exon to the third exon, long-fragment DNA of the fourth exon to the seventh exon, long-fragment DNA of the eighth exon to the eleventh exon and long-fragment DNA of the twelfth exon and the thirteenth exon. According to the kit and the method, the detection time is short and the workload is low.

The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 2 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 2-42 days.

The invention discloses a N-substituted benzyl tetrahydropyridine with -5-substituted indole and preparation method and application thereof, and the structure is shown in the general formula (I): substituted benzene methylamine (ethylamine) and methyl acrylate are raw materials, and an intermediate N-substituted benzylpiperidine (phenylethylpiperidine)-4-ketone is obtained by three steps of reaction such as Michael addition, Dieckmann condensation and hydrolysis decarboxylation or the like in sequence, and the object (I) is obtained by condensation reaction of the intermediate and 5-substituted indole. The compound (I) can effectively inhibit proliferation of human leukemia K562, Jurkat, U937, THP-1 cell line, the human esophagus cancer ECA-109 cell line, human liver cancer SMMC-7721 cell line, human ovary cancer HO-8910 cell line, human breast cancer MCF-7 cell line, breast cancer MDA-MB-231 cell line; the compound has a good metabolism stability in the human and rat liver microsomes; The compound does not have mechanical inhibition effects for five enzymes of human liver microsomes such as CYP3A4, CYP 2D6, CYP2C9, CYP1A2 and CYP2C19 or the like; the compound can induce the cell cycle G2/M retardance and promote cancer cell apoptosis and inhibit cancer cell propagation.

The present application provides for a compound of formula I, and related compounds, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods that include the administration of such compounds with at least one additional therapeutic agent.

The invention provides a method for deducting CYP3A4 gene expression quantity. The expression information of the CYP3A4 gene in human body can be deducted through detecting the methylation degree of a CpG site of the CYP3A4 gene in a human body blood DNA sample. The method is capable of deducting the activity of CYP3A4 enzyme in human body, explaining the individual difference of the drug effect and guiding the clinic and reasonable medication.

The present invention relates to piperidine or piperazine linked imidazole and triazole derivatives, compositions comprising said compounds, alone or in combination with other drugs, and methods of using the compounds for improving the pharmacokinetics of a drug. The compounds of the invention are useful in human and veterinary medicine for inhibiting CYP3A4 and for improving the pharmacokinetics of a therapeutic compound that is metabolized by CYP3A4.

Reference controls for use with pharmacogenomic testing, and methods for their identification, preparation, and use, are disclosed. The reference controls can confirm that pharmacogenomic testing correctly identifies individuals that do or do not have the mutation of interest, in both clinical trial and patient treatment settings. The reference controls can be selected to include one or more mutations to be identified, and prescreened to confirm that they bind to one or more of the primers used in the pharmacogenomic testing. The reference controls are human genomic DNA that includes certain identified polymorphisms (mutations) of interest, ideally derived from individuals, pre-selected and optionally properly consented, which have one or more of the polymorphism(s) of interest. The reference controls can be prepared by targeted pre-screening of human patients, by examining the genotype or genetic profile of the patients, isolating cells with the desired mutation, optionally immortalizing the cells, and obtaining DNA from the cells. The prescreening of prospective donors can be targeted based on any of a number of factors, such as genes of interest, mutations within the genes of interest, and membership in a specific ethnic or disease state population. The genomic DNA can be pre-screened for its ability to be detected, using a standard pharmacogenomic test, as including a specific mutation. Examples of mutations of interest include those present in a Phase I or Phase II metabolic enzyme such as CYP2D6, CYP2C19, CYP2C9, CYP2C8, and CYP3A5, CYP3A4, CYP2A6, CYP2B6, UGT1A1, DPD, ERCC1, MDR1, ADH2, NAT1 and NAT2 or any other metabolic or disease gene.

The invention provides novel application of a qi-tonifying and heart-rate-restoring preparation for injection and especially to application of the qi-tonifying and heart-rate-restoring preparation for injection in preparing medicines exerting induction action on the activity of the liver microsomes, CYP1A2 and CYP3A4.